Affiliation:
1. Pharmaceutical Research Department, F. Hoffmann-La Roche & Co., Ltd., Basel, Switzerland
Abstract
All the 28
Bacteroides fragilis
strains investigated were susceptible to sulfamethoxazole (minimal inhibitory concentration < 16 μg/ml) and resistant to trimethoprim (TMP; minimal inhibitory concentration > 4 μg/ml). Synergism between sulfamethoxazole and TMP was present in all strains at a ratio of 1:1. The few clostridia investigated proved more resistant to both compounds. Dihydrofolate reductases from
B. fragilis, C. perfringens
, and some other anaerobic species were isolated. Inhibition profiles with six structurally different inhibitors revealed major differences in all enzymes. For 50% inhibition, the enzyme from
B. fragilis
and all clostridia required concentrations of TMP which were between several hundredfold and 1,000-fold higher than those required for the enzyme of
Escherichia coli
, whereas the enzyme from
Propionibacterium acnes
only needed a threefold higher concentration. In vitro activities of TMP were seen to correspond to the activity at the enzymatic level in
B. fragilis
and
P. acnes
, but correspond to a much lesser extent to the activity at the enzymatic level in clostridia, where a poor penetration is assumed to be involved. Dihydrofolate reductase inhibitors other than TMP were found to be as active as TMP both at the enzyme and in vitro. In
B. fragilis
, higher concentrations of exogenous thymidine were required for increasing the minimal inhibitory concentration of TMP than in
E. coli
and probably also in
C. perfringens
.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献